ISRCTN04503926Completed未知

Effect of valsartan on endothelial function, carotid intima-media thickness, left ventricular mass, arterial compliance, inflammation and coagulation abnormalities in the metabolic syndrome

Central Manchester and Manchester Children's Hospitals NHS Trust (UK)0 sites120 target enrollmentStarted: February 7, 2008Last updated: May 8, 2017

Conditions

Trial Snapshot

No summary available.

•1. Individuals with metabolic syndrome without diabetes
•2. Male or female at least 18 years and less than 80 years
•3. Provision of signed informed consent form
•4. Females of child-bearing potential (i.e., females who are not chemically or surgically sterilised or females who are not post-menopause) must have a negative urine or blood pregnancy test at enrolment and be willing to use two methods of reliable contraception, one of which must be a barrier method

•1. Prior history of overt coronary artery disease, cardiac failure, peripheral vascular disease, cerebrovascular disease or diabetes
•2. History of significant renal or hepatic disease
•3. Pregnant or lactating women
•4. Severe hypertension (blood pressure [BP] greater than 180/110 mmHg)
•5. Current antihypertensive treatment
•6. Current drug therapy directly acting on the renin-angiotensin-aldosterone system
•7. Chronic anaemia (haemoglobin less than 10 g/L)
•8. Inadequate carotid ultrasonographic/echocardiographic images
•9. Excessive alcohol consumption
•10. Significant valvular disease
•11. History of primary myocardial disease, e.g. dilated cardiomyopathy, viral myocarditis, hypertrophic cardiomyopathy
•12. Previous enrolment or randomisation of treatment in the present study
•13. Participation in another investigational drug/interventional study in the last 30 days

Sponsor

Central Manchester and Manchester Children's Hospitals NHS Trust (UK)